Guidelines of the spanish society of cardiology for cardiovascular disease prevention and cardiac rehabilitation;Guias de practica clinica de la sociedad espanola de cardiologia en prevencion cardiovascular y rehabilitacion cardiaca

Revista Espanola de Cardiologia

Volumn 53, Issue 8, 2000, Pages 1095-1120

  Velasco, José A ^a   Cosín, Juan ^b   Maroto, José M ^b   Muńiz, Javier ^b   Casasnovas, José A ^b   Plaza, Ignacio ^b   Abadal, Luis Tomás ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b NONE

Author keywords

Cardiovascular diseases; Guidelines; Risk factors; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLOFIBRATE; CLOPIDOGREL; COLESTYRAMINE; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TICLOPIDINE;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; DIET RESTRICTION; DRUG INDUCED DISEASE; DYSLIPIDEMIA; HEART REHABILITATION; HUMAN; HYPERTENSION; MYOPATHY; OBESITY; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SYNDROME X; TOBACCO; ARTICLE; PRACTICE GUIDELINE; SMOKING CESSATION; SPAIN;

CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; SMOKING CESSATION; SPAIN;

EID: 0033851978     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(00)75211-0     Document Type: Review

References (138)

1. Pérez G, Pena A, Sala J, Roset P, Masiá R, Marrugat J et al. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. Int J Epidemiol 1998; 27: 599-604.
2. Tunsdall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
3. Muller C. Xantomata, hypercholesterolemia, angina pectoris. Acta Med Scan Suppl 1938; 89: 75.84.
4. Thannhauser SJ, Magendantz H. The different clinical groups of xanthomatous disease: a clinical physiological study of 22 cases. Ann Intern Med 1938; 11: 1662-1746.
5. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med 1971; 74: 1-12.
6. Martin MJ, Hulley SB, Brownwe WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implication from a cohort of 361, 662 men. Lancet 1986; 2: 933-939.
7. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Supl A): 2-11.
8. Bengtsson C. Ischaemic heart disease in women: a study based on a randomized population sample of women with myocardial infarction in Goteborg, Sweden. Acta Med Scand Suppl 1973; 549: 121-128.
9. Klag MJ, Ford DE, Mead LA, He J, Welton PK, Liang KY et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313-318.
10. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged > 62 years. Am J Cardiol 1994; 73: 702-703.
11. Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarrette smoking, serum cholesterol concentrations, and diastolic blood pressure among black and white males followed up for five years. Am Heart J 1984; 108: 759-769.
12. Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long term coronary prognosis after initial myocardial infarction: the Framingham heart Study. Am J Epidemiol 1989; 130: 469-480.
13. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein(a) are risk factors for major coronary events in mid-aged men. Am J Cardiol 1996; 77: 1179-1184.
14. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen male study. Circulation 1998; 97: 1029-1036.
15. Hokanson JE, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoproteine cholesterol level: a meta-analisis of population-based prospective studies. J cardiovasc Risk 1996; 3: 213-229.
16. Romm PA, Green CE, Reagan K, Rackley CE. Relation for serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 1991; 67: 479-483.
17. Plaza Pérez I, Villar Álvarez F, Mata López P, Pérez Jiménez F, Maiquez Galán A, Casasnovas Lenguas JA et al. Control de la colesterolemia en España 2000: un instrumento para la prevención cardiovascular. Rev Esp Cardiol 2000; 53: 815-837.
18. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of Coronary Heart Disease in clinical practice. Eur Heart J 1998; 19: 1434-1503.
19. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) ExPert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 1993; 269: 3015-3023.
20. Muñiz J, Juane R, Hervada J, López Rodríguez I, Castro Beiras A. Concentraciones séricas de colesterol en la población gallega de 40-69 años de edad. Clin Invest Arterioscl 1991; 3: 143-148.
21. Rodríguez JC, Calonge S, Bichara G. Prevalencia de los factores de riesgo de cardiopatía isquémica en la isla de Lanzarote. Med Clin (Barc) 1993; 101: 45-50.
22. Masía R, Pena A, Marrugat J, Sala J, Pavesi M, Covas et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Community Health 1998; 52: 707-715.
23. Löpez Miranda J, Ordovás JM, Pérez Jiménez F. Interacción genes-dieta como determinante de las concentraciones plasmáticas de colesterol. Med Clin (Barc) 1998; 111: 546-551.
24. Ros Rahola E, Fisac C, Pérez-Heras A. ¿Qué es realmente la dieta mediterránea? FMC 1998; 5: 557-571.
25. Varela G, Moreiras O, Carbajal A, Campo M. Encuesta de Presupuestos Familiares 1990-91. Estudio Nacional de Nutrición y Alimentación 1991. Tomo I. Madrid: Institute Nacional de Estadística, 1995.
26. Rodríguez Artalejo F, Banegas JR, Graciani MA, Hernández Vecino R, Rey Calero J. El consumo de alimentos y nutrientes en España en el període 1940-1988. Análisis de su consistencia con la dieta mediterránea. Med Clin (Barc) 1996; 106: 161-168.
27. Rodríguez Artalejo F, Graciani MA, Banegas JR. Martín-Moreno JM, Sabaté J, Rey Calero J. El consumo de alimentos y nutrientes en España en el període 1940-1988 (y II). Un estudio comparative de las principales fuentes de información sobre consumo alimentario. Med Clin (Barc) 1996; 107: 446-452.
28. Bartechi CE, MacKenzie TD, Scherier RW. The human costs of tobacco use (first of two parts). N Engl J Med 1994; 330: 907-912.
29. MacKenzie TD, Barcheti CE, Scherier RW. The human costs of tobacco use (second of two parts). N Engl J Med 1994; 330: 975-980.
30. Encuesta Nacional de Salud, 1992. Madrid: Ministerio de Sanidad y Consumo. Secretaría General Técnica. Centra de Publicaciones
31. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242-249.
32. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluative of the evidence. Br Med J 1997; 315: 973-982.
33. Liam TH, He Y. Passive smoking and coronary heart disease: a brief review. Clin Exp Pharmacol Physiol 1997; 24: 993-996.
34. Shah PK, Helfant RH. Smoking and coronary artery disease. Chest 1988; 94: 449-452.
35. López García Aranda V, García Rubira JC. Tabaco y cardiopatía isquémica. Programas de control del hábito. En: Maroto JM, De Pablo C, Artigao R, Morales MD, editores. Rehabilitación Cardíaca. Barcelona: Olalla Ediciones, 1999; 103-116.
36. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: An analysis of published data. Br Med J 1989; 298: 784-788.
37. Harats D, Ben Naim M, Dabach Y, Hollander G, Stein O, Stein Y et al. Cigarette smoking renders LDL susceptible to perixidatiive modification and enhanced metabolism by macrophages. Atherosclerosis 1989; 79: 245-252.
38. Heitzer T, Kurz S, Munzel T. Cigarette smoking potentiates endothelial dysfunction in patients with hypercholesterolemia. Circulation 1994; 90: 1513.
39. Blann AD. The acute influence of smoking on the endothelium. Atherosclerosis 1992; 96: 249-250.
40. McVeigh GE, Le May L, Morgan DJ, Cohn JN. Cigarette smoking inhibits basal but not stimulated release of nitric oxide from the forearm vasculature. J Am Coll Cardiol 1995; 25: 337A.
41. Keis A, editor. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge: Harvard University Press, 1980.
42. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406-1416
43. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986; 314: 271-275.
44. Galan KM, Deligonul U, Kern MJ, Chaitman BR, Vandormael MG. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61: 260-263.
45. García Rubira JC, Valverde B, Romero D, Gonzalez M, García Martínez JT, Cruz Fernández JM. El infarto de miocardio en la unidad coronaria: cambios en una década: influencia de la fibrinolisis y del aumento de camas. Rev Lat Cardiol 1996; 17: 12-15.
46. Barbash GI, White HD, Modan M, Díaz R, Hampton JR, Heikkila J et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation 1993; 87: 53-58.
47. Stamler R, Stambler J, Grimm R. Nutritional therapy for high blood pressure. Final report of a four year randomized controlled trial. The Hypertension Control Program. JAMA 1987; 257: 1484-1491.
48. The Trials of Hypertension Prevention Collaborative Research Group. The effects of non-pharmacologic interventions on blood pressure of persons with high normal levels: results of the trials of hypertension prevention. Phase I. JAMA 1992; 267: 1213-1220.
49. Grimm RH Jr., Grandits GA, Cutler JA, for the TOHMS research group. Relationship of quality of life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study. Arch Intern Med 1997; 157: 638-648.
50. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
51. Collins R, Peto R, McMahon S. Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
52. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence of 1994. Vasc Med Biol 1994; 4: 265-271.
53. Sytkowski PA, D'Agostino RB, Berlanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697-703.
54. Haffner SM, Lehtos S. Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
55. Malmberg K, Rydén L, Efendic S. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI) Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
56. Hypertension Detection and Follow-up programe cooperative group. The effect of treatment on mortality in mild hypertension. N Engl J Med 1982; 307: 976-980.
57. Scandinavian Sinvastatin Survival Group. Randomized trial of cholesterol lowering 4.444 patients with coronary heart disease The Scandinavian Sinvastatin Survival Study. Lancet 1994; 344: 1383-1389.
58. Sacks FM, Pteffer MA, Moye LA, Rouleau JL, Rutherford JD. Cole TG et al. The effect of pravastatin on coronary events after myocardial infartion in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
59. Larson B. Obesity and body fat distribution as predictors of coronary heart disease. En: Marmot M, Elliott P, editores. Coronary heart disease epidemiology. From aetiology to public health. Oxford: Oxford University Press, 1992; 233-241.
60. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
61. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality in healthy middel-aged Norwegian men. N Engl J Med 1993; 328: 553-557
62. Paffenbarger R Jr., Hyde RT, Wing A. Lee I-Mlu, Jung DL, Kampert JB. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-545.
63. Berling JA, Colditz CA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-628.
64. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM. An overview of randomized trials of rehabilitation with exercice after myocardial infarction. Circulation 1989; 80: 234-244.
65. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-162.
66. Lynch JW, Kaplan GA, Cohen RD, Toumiletho J, Salonen JT. Do cardiovascular risk factors explain de relation between socio-economic status, risk of all cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996; 144: 934-942.
67. Williams RB, Haney TL, Lee KL, Kong YH, Blumenthal JA, Whalen RE. Type A Behaviour, hostility and coronary atherosclerosis. Psychos Med 1980; 42: 539-563.
68. Cardiovascular disease risk factors: new areas for research. Report of a WHO Scientific Group. WHO Technical Report Series 841. Ginebra: World Health Organization, 1994.
69. Yarnell JWG, Baker JA, Sweetman PM, Bainton D, O'Brien JR, Whitehead PJ et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart disease; the Caerphilly and Speewell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-844.
70. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis an Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 461-466.
71. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
72. Danesh J. Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436.
73. Malinow MR, Boston AG, Krauss RM. Homocysteine. Diet, and Cardiovascular Disease. A Statement for Healthcare Professionals From the Nutrition Committee. American Heart Association. Circulation 1999; 99: 178-182.
74. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1998; 28: 1328-1428.
75. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Eur Heart J 1994; 15: 1300-1331 : Atherosclerosis 1994; 110: 121-161.
76. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Eur Heart J 1994; 15: 1300-1331 : Atherosclerosis 1994; 110: 121-161.
77. Velasco Rami JA, Ferreira Montero I. Tomás Abadal L. Prevención secundaria de la cardiopatía isquémica. En: Normas de actuación clínica en Cardiología. Madrid: Sociedad Española de Cardiologĩa, 1996; 359-362.
78. Hujihregts P, Feskens E, Rasanen L, Fidanza F, Nissinen A, Menott A et al. Dietary pattern and 20 year mortality in elderly men in Finland. Italy, and the Netherlands: Longitudinal cohort study. Br Med J 1997; 315: 13-27.
79. Trichopoulou A, Kouris-Blazos A. Wahlquist ML, Gnardellis C, Lagiou P, Polychronopoulos E et al. Diet and overall survival in elderly people. Br Med J 1995; 311: 1457-1460.
80. Lipid Researchs Clinics Program: The lipid Researchs Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary disease. JAMA 1984; 251: 351-364.
81. Berusike JE, Levy RI, Kelsey SF, Passumany ER, Richardson JM. Loh IK et al. Effects of therapy with cholestyramine on progression of coronary arterioclerosis: results of the NH LB. tvpe II Coronary Intervention Study. Circulation 1984; 69: 313-324.
82. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LD et al. Effect on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the ST. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.
83. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin JT, Kaplan C et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
84. Blakenhorn PH, Nessinn SA, Johnson RL, Sanmarco ME, Aren SP, Cashin-Hemphill L et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-3240.
85. Frick MH, Elo O, Haapa K, Heinsalmi P. Helo P, Huttunen JK et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
86. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L et al. The Helsinki Heart Study: an 8.5 year safety and mortality follow-up. J Intern Med 1994; 235: 31-39.
87. Pedersen TR, Olson AG, Faegerman O, Kjekshus J, Wedel H, Berj K et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvaslatin Survuval Study (4S). Circulation 1998; 97: 1453-1460.
88. The long term intervention with pravastatin in ischaemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
89. Shepherd J, Cobbe S, Ford I, Isles G, Lorimer AR, Macfarlan PW. Prevention of coronary heart disease with pravastatin in men with hypercolesterolemia. N Engl J Med 1995; 333: 1301-1307.
90. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-1622.
91. The Post CABG Trials Investigators. The effect of aggresive lowering of cLDL levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
92. Rigotti NA, Pasternak RC. Tabaquismo de cigarrillos y cardiopatia coronaria. Riesgos y tratamiento. En: Abrams J, Pasternak RC, editores. Modificación de la evolución natural de la coronariopatía. Factores de riesgo y su modificación. Clínicas Cardiológicas de Norteamérica 1996; 53-70.
93. Scharwtz JL. Review and evaluation of smoking cessation methods. Bethesda, Md: National Cancer Institute, 1987.
94. Use of nicotine to stop smoking. Medical Letter 1995; 37: 6-8.
95. Working Group for the Study of Transdermal Nicotine in Patients With Coronary Artery Disease: Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-995.
96. Fagerström KO. Mesuring degree of physical dependence to tobacco with reference to individualization to treatment. Addit Behav 1978,3: 235-241.
97. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetics on the development and progress of the long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
98. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthew DR et al, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary heart disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br Med J 1998; 316: 823-828.
99. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
100. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
101. Hambrecht R, Niebauer J, Marburger CH, Grunze M, Kalberer B, Hauer K et al. Diferentes intensidades de actividad física durante el tiempo de ocio en pacientes con enfermedad coronaria: efectos sobre la función cardiorrespiratoria y la progresión de las lesiones coronarias ateroscleróticas. J Am Coll Cardiol 1994; 3: 34-43.
102. Borg G. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 14: 377-381.
103. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of Aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-669.
104. Persantine-Aspirin Reinfarction Study Research Group. Persantine-Aspirin reinfarction study. Circulation 1980; 62: 449-461.
105. Klint CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-257.
106. Antiplatelet Trialist Collaborative. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296-304.
107. Antiplatelet Trialist Collaborative. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-87.
108. Cairns JA, Hirsh J, Lewis HDJ, Resnekov L, Theroux P. Anti-thrombotic agents in coronary artery disease. Chest 1992; 102 (Supl): 4S-6S.
109. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (Caprie). Lancet 1996; 348: 1329-1339.
110. Cruz-Fernández JM, López-Bescós L, García-Dorado D, López García-Aranda V, Cabadés A, Martín-Jadraque L et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-465.
111. Jusuf S. B-Blockade. A significant impact on prognosis. Abingdon: The Medicine Publishing Company, 1997.
112. Gottlieb SE, McCarter RJ, Vogel RA. Effect of betablockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
113. Beta-Blocker Heart Attack trial Research Group. A randomized trial of propanolol in patients with acute myocardial infarction. Mortalily results. JAMA 1982; 247: 1707-1714.
114. Aronow WS. Prevalence of use of B-Blockers and calciun channel bloquecks in older patiens with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1996; 44: 1075-1077.
115. Gundersen T, Kjekshus J. Tiniolol treatment after myocardial infarction in diabetic patiens. Diabetes Care 1983; 6: 285-290.
116. Malmberg K, Herlit J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction; retrospective date from two longs studies. Eur Heart J 1989; 10: 423-428.
117. Anderson JL, Rodier HE, Green LS. Comparative effects of B-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983; 51: 1196-1202.
118. CONSENSUS Trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
119. The SOLVD investigators. Effect of enalapril on survival in patiens with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
120. Pfeffer MA. Braunwald E, Move CA, Basta L, Brown EJ Jr, Cuddy TE et al. on behalf of the SAVE Investigations: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocarcial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
121. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of CHF. Lancet 1993; 342: 821-827.
122. Gruppo Italiano per lo Studio della Sopravivenza nell'infarcto Miocardico GISS-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
123. Kober L, Pedersen C, Carlen E, Bagger H, Eliasen P, Lyngborg K et al. for the Trandolapril cardiac evaluation (TRACE) study group. A Clinical Trial of the angiotensin-converting enzyme inhibitor tandolapril in patiens with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
124. Sacks FM, Moye LA, Barry R, Davis BR, Cole TG, Rouleau JL et al. Relationship between plane LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97: 1446-1452.
125. Rosenson KS, Tangney CC. Antiatherothrombotic properties of statin. Implication for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
126. World Health Organization: Technical Report Series 270. Rehabilitation of patients with cardiovascular diseases. Ginebra: Report of WHO expert committee, 1964.
127. Velasco JA, Maureira JJ, editores. Rehabilitación del paciente cardíaco. Barcelona: Ed. Doyma, 1993.
128. Maroto JM, De Pablo C, Artigao R, Morales M. editores. Rehabilitación cardíaca. Barcelona: Eidiciones Olalla, 1999.
129. Oldridge NB, Guyatt GH, Fisher ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomised clinical trials. JAMA 1988; 260: 945-950
130. Oldridge N, Furlang W, Feeny D, Torrance G, Guyatt G, Croug J et al. Economic evaluation of Cardiac Rehabilitation soon after Acute Miocardial Infarction. Am J Cardiol 1993; 72: 154-161.
131. Maroto JM, De Pablo C, Aitigao R, Morales MD. Rehabilitación cardíaca. Análisis de coste-efectividad. Rev Esp Cardiol 1996; 49: 753-758.
132. Plaza I, Gómez JA. Cambio de actitud de los cardiólogos españoles con respecta al tratamiento hipolipemiante en prevención secundaria. Clin Invest Arterioscler 1999; 11: 8-15.
133. Plaza I, Velasco JA, Maroto JM. Prevención secundaria y rehabilitación cardíaca en España. Rev Esp Cardiol 1996; 49: 549-553.
134. ASPIRE Steering Group. A British Cardiac Society survey of the potential for secondary prevention of coronary heart disease. Principal results. Heart 1996; 75: 334-342.
135. Velasco JA, Cosín J, López Sendón JL, De Teresa E, De Oya M, Carrasco JL et al, en nombre del Grupo de Investigadores del Estudio PREVESE. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol 1997; 50: 406-415.
136. Muñiz J, Juane R, Garcíd;a M, Virgós A, Vázquez JM, Castro Beiras A, for the RIGA Investigators group. Treatment of hipercholesterolemia at discharge from hospital after a agude miocardial infuction in a coronary heart disease low incidence area: Galicia (North-west of Spain). CVD Prevention 1998; 1: 129-137.
137. PREVENIR Study. Results. Bristol-Myers Squibb Company, data on files.
138. EUROASPIRE Study Group. EUROASPIRE, a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-1582.